
Steven M Bair MD
Clinical Fellow in Hematology/Oncology at the Hospital of the University of Pennsylvania
Request appointment
1665 Aurora CtAurora, CO 80045
Fax+1 720-848-1786
Overview of Dr. Bair
Dr. Steven Bair is a hematologist in Aurora, CO and is affiliated with UCHealth University of Colorado Hospital. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 12 years. He is one of 24 doctors at UCHealth University of Colorado Hospital who specialize in Hematology. He has more than 20 publications and over 500 citings.
Education & Training
University of PennsylvaniaMSCE, Clinical Epidemiology, 2018 - 2020
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2017 - 2020
University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2017
Case Western Reserve University School of MedicineClass of 2014
Certifications & Licensure
CO State Medical License 2020 - 2027
WY State Medical License 2021 - 2027
PA State Medical License 2014 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- The Myron F. Kanter and Lawrence J. Kanter Endowment Award (Cardiology) Case Western Reserve University School of Medicine, 2014
- Alpha Omega Alpha Inductee Alpha Omega Alpha, 2014
Publications & Presentations
PubMed
- Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.Allison M Bock, Lei Feng, Ayushi Chauhan, Lorenzo Falchi, Reid Merryman
Blood Advances. 2026-08-25 - Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma.Steven M Bair, Navin Pinto, Andrew Roth, Michael Verneris, Bradley Haverkos
Transplantation and Cellular Therapy. 2026-06-03 - Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma.Karan L Chohan, Rina L Welkie, James Godfrey, Steven Bair, Lorenzo Falchi
Blood Cancer Journal. 2026-05-22
Abstracts/Posters
- Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell LymphomasSteven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Steven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
The Utility of FDG-PET in the Treatment of Hodgkin LymphomaNovember 6th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









